Compounds having the formula: ##STR00001## are disclosed. M.sup.1 and M.sup.2 are the same or different and are transition metal atoms or ions; Z.sup.2 and Z.sup.3, independently, are the atoms necessary to complete a 3 12 membered heterocyclic ring; Z.sup.1 is an alkylene or arylene group; Q.sup.1 and Q.sup.2 are the same or different and are electron withdrawing groups; L.sup.1 and L.sup.3, taken together, represent --O--CR.sup.13--O--; L.sup.2 and L.sup.4, taken together, represent --O--CR.sup.14--O--; and R.sup.13 and R.sup.14 are the same or different and are selected from the group consisting of alkyl groups and aryl groups or R.sup.13 and R.sup.14 represent alkylene or arylene groups that are directly or indirectly bonded to one another. Methods for making such compounds are also disclosed, as are intermediates which can be used in their preparation. Also disclosed are methods for carrying out C--H insertion reactions using bis-transition metal catalysts, such as the above compounds. Procedures for preparing d-threo methylphenidate, tolterodine, CDP-840, nominfensine, and sertraline, are described.

 
Web www.patentalert.com

< Antibodies to human vascular endothelial growth factor 2

< 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors

> Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same

> Stabilized viral envelope proteins and uses thereof

~ 00286